Recent 8-K filings for EDAP
Highest-materiality recent filing
EDAP reports record 2025 HIFU revenue up 39% YoY; net loss widens, FY2026 guidance reaffirmed
- HIFU revenue €33.1M in FY2025, +39% YoY; Focal One placements up 69% YoY.
- Q4 HIFU revenue €11.7M (+34% YoY); Q4 U.S. procedures grew 28% YoY.
-
EDAP TMS shareholders approve bylaw amendments, reject two say-on-pay frequency options
All six director nominees re-elected; Ryan Rhodes, Lance Willsey, Fran Schulz, Josh Levine, and David Horn confirmed.
-
Presentation at June 1, 2026 Investor Day highlights strategic shift to High Intensity Focused Ultrasound (HIFU) devices.
-
EDAP TMS rebrands as FocalTherics, ticker to FOCL June 1; ESWL/Distribution discontinued ops
Corporate name changes to FocalTherics; ticker symbol switches from EDAP to FOCL effective June 1, 2026.
-
EDAP Q1 2026: record HIFU revenue $11.6M (+78% YoY); net loss $9.1M
HIFU revenue $11.6M, up 78% YoY; total revenue $17.8M vs $14.3M in Q1 2025.
-
EDAP TMS draws €12M second tranche from EIB credit facility; issues warrants at €3.23 strike
Drawdown of €12.0 million under Tranche B of EIB credit facility, expected disbursement late April 2026.
-
EDAP reports record 2025 HIFU revenue up 39% YoY; net loss widens, FY2026 guidance reaffirmed
HIFU revenue €33.1M in FY2025, +39% YoY; Focal One placements up 69% YoY.
-
EDAP TMS highlights 87 Focal One installs, 29% procedure CAGR in Oppenheimer presentation
87 Focal One systems installed globally (42 academic, 45 community) as of Dec. 31, 2025.
-
EDAP appoints David Horn to Board; Glen French resigns
Glen French resigned from EDAP Board and all committees effective Feb 10, 2026; resignation not due to any dispute.
-
EDAP reports record Q4 HIFU revenue $12.9-13.3M; issues 2026 guidance $50-54M
Q4 HIFU revenue $12.9-13.3M (record); FY2025 HIFU revenue $36.7-37.2M, up 36-38% YoY.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.75 · Median 0.60 · Most common event other_material